Cancer Research · 2007 · 72 citations · 44 references
Life SciencesMolecular BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingGrowth Factor SignalingOncogenic Signaling PathwaysReceptor Tyrosine Kinase SignalingSignal Transduction In CancerEpidermal Growth Factor Receptor SignalingPhosphorylation-dependent RegulationPlatelet-derived Growth Factor Receptor SignalingPlatelet-derived Growth Factor ReceptorsSteroid Receptor CoactivatorsTyrosine Phosphorylation Signaling
The steroid receptor coactivator amplified in breast cancer 1 (AIB1) as well as epidermal growth factor receptor (EGFR) family members are frequently overexpressed in epithelial tumors, and their expression is associated with poor prognosis. However, a direct role of AIB1 in EGF signaling has not been determined. To address this, we reduced endogenous AIB1 levels using RNA interference in lung, breast, and pancreatic cancer cell lines. We found that a knockdown of AIB1 levels resulted in a loss of the growth response of these cell lines to EGF. Further analysis revealed that the depletion of AIB1 reduced tyrosine phosphorylation of EGFR at multiple residues both at autophosphorylation and Src kinase phosphorylation sites. AIB1 knockdown did not affect tyrosine phosphorylation of the receptor tyrosine kinases, platelet-derived growth factor receptor and HER3, or overall tyrosine phosphorylation of cellular proteins. However, EGF-dependent phosphorylation of HER2 was decreased. EGFR levels and membrane trafficking were not changed by AIB1 depletion, but there was less recruitment of Src homology 2 domain-containing proteins to the EGFR. This led to a substantial reduction in EGF-induced phosphorylation of signal transducers and activators of transcription 5 and c-Jun NH(2)-terminal kinase but no significant change in the activation of AKT. Vanadate treatment of cells revealed that the reduction in EGFR tyrosine phosphorylation is dependent in part on changes in cellular phosphatase activity. We propose that a portion of the oncogenic effect of AIB1 could be through control of EGFR and HER2 activity and subsequent modulation of cellular signaling pathways.
44
Patterns of somatic mutation in human cancer genomes
Christopher Greenman, Philip Stephens, Raffaella Smith et al. · Nature · 2007 · 3.1K citations · Full text
Life Sciences, Genetics, Oncology +14
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Sarah L. Anzick, Juha Kononen, Robert L. Walker et al. · Science · 1997 · 1.7K citations
Gefitinib-Sensitizing <i>EGFR</i> Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Raffaella Sordella, Daphne W. Bell, Daniel A. Haber et al. · Science · 2004 · 1.6K citations
Medicine, Oncology, Pharmacology +17